Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.

GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...

Shares of GlaxoSmithKline Pharmaceuticals Ltd ended at ₹2,608, up by ₹275.75, or 11.82%, on the BSE. Brokerage firms, ...

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

Dr. Juliet Addo, Academic Engagement Director for Ghana and Head of the Africa Open Lab at GSK, has reaffirmed the importance ...

GSK Pharma had reported a consolidated net profit of Rs 230 crore for Q3 FY25. This marks a significant surge of nearly 400 ...

SK Biopharma recruits GSK experts to boost US research and development SK Biopharma enhances its US operations by enlisting ...

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

The company's total revenue also saw a rise. In the previous year's Q3 or Q3FY24, the total revenue attained by the company stood at Rs 805.26 crore. This rose to Rs 949.42 crore in the span of a year ...

GSK Pharma delivered a better-than-expected performance in Q3, largely driven by robust volume growth in the general medicine ...